The CONVINCE trial of the anti-inflammatory drug colchicine missed its primary endpoint, but secondary analyses suggested benefit.
BASEL, SWITZERLAND — The anti-inflammatory agent colchicine failed to show significant benefit in the treatment of patients with non-cardioembolic ischemic stroke in the primary analysis of the CONVINCE trial.
Inflammation, he said, plays an important role in the pathophysiology of atherosclerotic plaque, a major cause of cardiovascular events and ischemic strokes. Conducted in 16 European countries and Canada, the CONVINCE trial included 3154 patients with a recent non-cardioembolic nondisabling ischemic stroke or high-risk transient ischemic attack. They were randomly assigned to receive colchicine or placebo.
Results of the primary intention-to-treat analysis showed that the primary endpoint occurred in 153 patients randomized to low-dose colchicine vs 185 in the placebo group . This translated into a hazard ratio of 0.84 , colchicine did show a significant benefit in the primary endpoint .In addition, significantly reduced rates of recurrent stroke or cardiovascular events were observed in the subgroup of patients with a history of coronary artery disease.
He pointed out that the COVID pandemic reduced the planned follow-up time in the CONVINCE trial, which led to the study being underpowered for the primary analysis.
Cerebrovascular Accident CVA - Cerebrovascular Accident Thromboembolism Cardiometabolic Risk Cardiometabolic Risk Factors Ischemic Stroke Ischaemic Stroke Atherosclerotic Heart Disease Atherosclerotic Cardiovascular Disease Coronary Heart Disease Ischemic Heart Disease Coronary Artery Disease Atherosclerosis Atherosclerotic Disease Of The Carotid Artery Arteries Recurrent Stroke
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
More Support for Tenecteplase in Ischemic StrokeThe TASTE trial adds to a string of previous trials showing non-inferiority of tenecteplase to alteplase. In addition, an updated meta-analysis suggests tenecteplase is superior.
Read more »
Guidelines on Rapid BP Reduction in Acute Ischemic Stroke ChallengedA new study challenges guideline recommendations to rapidly reduce BP in acute ischemic stroke patients to allow for swift thrombolysis.
Read more »
Bleeding Risk Clarified in Patients With Ischemic Stroke Receiving tPAAntiplatelet therapies increased the risk for intracranial hemorrhage in patients with stroke receiving thrombolysis, but the absolute increased risk was small.
Read more »
New tool decodes complex, single-cell genomic dataUnlocking biological information from complex single-cell genomic data has just become easier and more precise, thanks to the innovative scLENS tool developed by the Biomedical Mathematics Group within the IBS Center for Mathematical and Computational Sciences led by Chief Investigator Kim Jae Kyoung, who is also a Professor at KAIST.
Read more »
APS introduces new fire tool that may result in temporarily shutting down powerJorge Torres is the weekday afternoon meteorologist on ABC15.
Read more »
New firefighting tool unveils in North County as Wildfire Awareness Month startsOfficials in North County unveiled a new firefighting tool Tuesday just in time for Wildfire Awareness Month in May. Cal Fire said it will help cut water reloading turnaround time in half.
Read more »